In particular, our in silico and in situ studies demonstrate that MUC1 (EMA) could be an attractive target in PSMA-negative tumors, since on the patient, metastasis, and individual tumor cell levels, we observed an inverse correlation between MUC1 and PSMA expression. Here, FOLH1 is linked to neoplasm.